Wyche Coleman
Ophthalmology · Shreveport, LANPI 1841491826
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $26,950 of the $35,104 with a category attached, or 76.8%. Alcon Research LLC accounts for 64.0% of it on its own, with 24 other manufacturers making up the rest. Reporting peaked in 2024 at $17,457 and has fallen 64.6% since, to $6,182 in 2025. Among ophthalmology clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 233 payments — averaging $150.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon Research LLC$22K
- Alcon$8K
- Glaukos Corporation$808
- Biotissue Holdings Inc.$623
- Sight Sciences, Inc.$506
- Ivantis, Inc$353
- plus $2K from 19 others
Across 165 payments — averaging $575.07 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Alcon Research LLC$88K
- Glaukos Corporation$7K
What the payments were for
- Consulting fees$26,95077%
- Travel & lodging$5201%
- Food & beverage$7,59822%
- Gifts$360%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon Research LLC | 11 | $22,450 |
| Alcon | 94 | $8,467 |
| Glaukos Corporation | 15 | $808 |
| Biotissue Holdings Inc. | 15 | $623 |
| Sight Sciences, Inc. | 22 | $506 |
| Ivantis, Inc | 8 | $353 |
| AbbVie | 12 | $290 |
| Oyster Point Pharma, Inc. | 9 | $278 |
| Rxsight Inc | 7 | $270 |
| Novartis | 8 | $184 |
| Lensar, Inc. | 1 | $125 |
| Kala Pharmaceuticals, Inc. | 1 | $124 |
| Aerie Pharmaceuticals, Inc. | 7 | $115 |
| Bausch & Lomb Americas Inc. | 5 | $100 |
| Amgen | 2 | $86 |
| Carl Zeiss Meditec, Inc. | 1 | $76 |
| NEW World Medical,inc. | 5 | $56 |
| Carl Zeiss Meditec USA, Inc. | 1 | $36 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $33 |
| Ocular Therapeutix, Inc. | 2 | $28 |
| Mallinckrodt Hospital Products Inc. | 1 | $23 |
| E.r. Squibb & Sons, L.L.C. | 1 | $20 |
| Lilly USA, LLC | 1 | $19 |
| Shire North American Group Inc | 1 | $18 |
| Averitas Pharma Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NGENUITY$6,793
- ARGOS$356
- Clareon$288
- AcrySof IQ PanOptix$256
- iDoseTR$214
- RXSIGHT INJECTOR HANDPIECE$163
- RXSIGHT CONTACT LENS$163
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$163
- LIGHT ADJUSTABLE LENS (LAL)$163
- RXSIGHT INJECTOR CARTRIDGE$163
- ReSTOR$144
- iStent inject W$128
- KXL System$128
- Photrexa$128
- Centurion$127
- LENSAR LASER SYSTEM$125
- TYRVAYA$125
- EYSUVIS$124
- OMNI$121
- Hydrus Microstent$113
How this compares
$35,104 in reported general payments places this provider in the 95th percentile of 286 ophthalmology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 23 | $23,799 |
| CombiganBrimonidine Tartrate/Timolol | 30 | $9,893 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 50 | $9,067 |
| VyzultaLatanoprostene Bunod | 13 | $7,068 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 20 | $5,025 |
| Prednisolone Acetate | 124 | $3,929 |
| Latanoprost | 324 | $3,698 |
| Brimonidine Tartrate | 148 | $2,286 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 149 | $2,217 |
| Ketorolac Tromethamine | 103 | $2,050 |
| Timolol Maleate | 184 | $1,243 |
| Dorzolamide Hcl | 62 | $1,216 |
| Acetazolamide | 24 | $758 |
| Pantoprazole Sodium | 36 | $303 |
| Atorvastatin Calcium | 29 | $296 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Combigan | $290 | $33,69253 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $100 | $7,06813 claims |
| AlconSimbrinza | $8,467 | $5,02520 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 286 ophthalmology providers in Louisiana.
Other ophthalmology in Shreveport
- Bryan VekoviusShreveport$29K
- Christopher ShelbyShreveport$27K
- Chanping LiangShreveport$15K
- Claude BundrickShreveport$12K
- Bryan LuskShreveport$10K
- Arthur KavanaughShreveport$7K
- Ann GuyShreveport$6K
- Jeffrey LuskShreveport$5K
- John CarmodyShreveport$5K
- Blake WilliamsonBaton Rouge$443K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.